S&P 500
3,258.78+12.19(+0.38%)Nasdaq
10,764.38+92.11(+0.86%)Russell 2000
1,465.62+13.80(+0.95%)
OpGen, Inc. (OPGN)
- GlobeNewswire
OpGen, Inc. Announces Notice of Annual Meeting Venue Change
GAITHERSBURG, Md., Sept. 18, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due to continuing health and safety considerations arising from the COVID-19 pandemic. As a result, the Company’s 2020 Annual Meeting of Stockholders will now be held at OpGen’s corporate headquarters at 708 Quince Orchard Road, Gaithersburg, Maryland 20878. The Company’s 2020 Annual Meeting of Stockholders will be held, as scheduled, on Wednesday, September 30, 2020 at 10 a.m. ET. As noted in the proxy statement filed by the Company on August 20, 2020, stockholders of record as of end of business on August 17, 2020 may continue to vote at http://www.pstvote.com/opgen2020, by phone, and by mail until 11:59 p.m. ET on September 29, 2020, in accordance with the instructions provided in the proxy materials.For stockholders who intend to attend the 2020 Annual Meeting of Stockholders in person and are legally permitted to do so, the Company respectfully requests that they contact the Company’s corporate offices at (240) 813-1260 no later than 5 p.m. ET on Monday, September 28, 2020 so that the Company can be appropriately prepared. The Company advises that stockholders who are experiencing any potential COVID-19 symptoms or who have been in contact with any person experiencing any potential COVID-19 symptoms should not attend the annual meeting in person. The Company may put in place additional procedures or limitations on meeting attendees, including limiting seating, requiring health screenings, protective masks and other reasonable or required measures in order to enter the meeting location.For further information, please refer to the Company’s Notice of 2020 Annual Meeting of Stockholders and Proxy Statement, filed with the Securities and Exchange Commission on August 20, 2020, which can be accessed at http://ir.opgen.com/sec-filings.About OpGen, Inc.OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.For more information, please visit www.opgen.com.Forward-Looking Statements by OpGenThis press release includes statements regarding the OpGen’s 2020 Annual Meeting of Stockholders. These statements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the realization of expected benefits of our business combination transaction with Curetis GmbH, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.OpGen Contact: Oliver Schacht CEO InvestorRelations@opgen.comPress Contact: Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.comInvestor Contact: Megan Paul Edison Group mpaul@edisongroup.com
- GlobeNewswire
Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing
Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical PracticeVIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that scientists at its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”), in collaboration with researchers from the Johns Hopkins University School of Medicine, have published a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.P. aeruginosa is listed by the World Health Organization as critical priority pathogen. To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel β-lactam-β-lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014. While pre-clinical investigations indicated ceftolozane-tazobactam activity against approximately 85%-95% of U.S. and Canadian carbapenem-non-susceptible P. aeruginosa isolates, soon after the clinical introduction of ceftolozane-tazobactam, reports of resistance during therapy emerged.The study published in Clinical Infectious Diseases sought to understand mechanisms of resistance leading to ceftolozane-tazobactam resistance, the frequency of cross-resistance between ceftolozane-tazobactam and other novel beta-lactam beta-lactamase inhibitor combinations and identify modifiable risk factors that may slow or prevent the acquisition of ceftolozane-tazobactam resistance. Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam. Mutations identified in ceftolozane-tazobactam resistant isolates involved, amongst others, AmpC, a known binding site for ceftolozane, PBP3, the target of ceftolozane, and DNA polymerase. The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing. Earlier this year, Dr. Patricia Simner of Johns Hopkins Medicine and Ares Genetics presented results from a study assessing the potential of long-read sequencing to predict antimicrobial susceptibility results at the online ASM Microbe 2020 meeting.Dr. Andreas Posch, CEO Ares Genetics and co-author of both studies, commented, “While we have already shown that NGS allows for CLIA-compliant identification of bacterial pathogens and antimicrobial resistance markers as well as accurate prediction of phenotypic resistance in previous publications, the present studies further underline the diagnostic value of NGS as well as the need for rapid antimicrobial resistance testing and improving antibiotic treatment regiments. I am particularly excited about our joint work on using long-read sequencing technology for phenotype prediction as this technology could potentially allow for molecular antibiotic susceptibility testing directly from native patient samples in just a few hours.”About OpGen, Inc. OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.For more information, please visit www.opgen.com.Forward-Looking Statements by OpGenThis press release includes statements regarding studies and publications of OpGen’s subsidiary Ares Genetics GmbH. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.OpGen Contact: Oliver Schacht CEO InvestorRelations@opgen.comPress Contact: Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.comInvestor Contact: Megan Paul Edison Group mpaul@edisongroup.com
- GlobeNewswire
OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test
Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic Affairs ARESupa – Universal Pathogenome Assay nominated by expert jury for Austria’s most distinguished innovation awardVIENNA, Austria, and GAITHERSBURG, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has been nominated for the 40th Austrian Innovation Award (Ref. 1).Ares Genetics has been selected by an expert jury as one of six finalists for its artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST) marketed under the brand name ARESupa – Universal Pathogenome Assay. The Austrian Innovation Award is awarded by the Federal Ministry for Digital and Economic Affairs and represents Austria’s most distinguished award for innovative companies. In a press release announcing the nominees (Ref. 1), Federal Minister for Digital and Economic Affairs Margarete Schramböck was quoted, “For the 40th time, the Ministry of Digital and Economic Affairs awards the Austrian Innovation Award for outstanding innovations and top achievements. Particularly in current times, innovation plays a very important role: The [nominated] companies strengthen the competitiveness of [Austria as a] business hub and thereby sustainably secure jobs. Moreover, innovative projects are of particular importance to jointly emerge stronger from the current [Covid-19] crisis.” Information on antibiotic susceptibility of pathogens is of utmost importance for clinical practice, epidemiology and public health purposes as well as for the development of pharmaceutical products in the infectious disease sector. Ares Genetics has therefore developed the ARESupa – Universal Pathogenome Assay, which is capable of accurately predicting antibiotic susceptibility via AI-powered interpretation of high-throughput DNA sequencing data as demonstrated in a recent multi-center US study (Ref. 2). The ARESupa is based on whole-genome sequencing of bacterial strains isolated from clinical specimens, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. ARESdb covers genomes of more than 55,000 bacterial strains and associated susceptibility data for more than 100 different antibiotics.The ARESupa had already been recognized with the MERCUR Innovation Award in the category Life Sciences 2019 (Ref. 3) and is currently offered by Ares Genetics for non-diagnostic applications in epidemiology, infection control, and outbreak analysis for customers in the public health sector and the pharmaceutical industry through the Company’s AI-powered bioinformatics platform www.ares-genetics.cloud.References 1. https://www.ots.at/presseaussendung/OTS_20200903_OTS0052/schramboeck-sechs-unternehmen-fuer-staatspreis-innovation-2020-nominiert Please refer to the original press release for the original statement by the Federal Minister for Digital and Economic Affairs Margarete Schramböck in German. The statement included here represents an unauthorized convenience translation. 2. Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. Ines Ferreira, Stephan Beisken, Lukas Lueftinger, Thomas Weinmaier, Matthias Klein, Johannes Bacher, Robin Patel, Arndt von Haeseler and Andreas E. Posch. 2020. Journal of Clinical Microbiology 58(7): e00273-20. 3. https://news.wko.at/news/wien/MERCUR-Innovationspreis:-Wirtschaftskammer-Wien-zeichnet-in.htmlAbout OpGen, Inc. OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.For more information, please visit www.opgen.com. Forward-Looking Statements by OpGenThis press release includes statements regarding the nomination of OpGen’s subsidiary Ares Genetics GmbH for the Austrian national innovation award and Ares Genetics’ molecular antibiotic susceptibility test, ARESupa. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.OpGen Contact: Oliver Schacht CEO InvestorRelations@opgen.com Press Contact: Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.comInvestor Contact: Megan Paul Edison Group mpaul@edisongroup.com
